Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

• "When-issued" trading expected to begin on or about June 12, 2024
• Record date for distribution of GRAIL shares will be June 13, 2024
• Distribution date for GRAIL shares anticipated to be June 24, 2024

Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024 and has applied to list on Nasdaq as "GRAL."

"Today's announcement marks a milestone for Illumina and signals an important step forward for the company, since the divestiture of GRAIL is one of our 2024 priorities," said Jacob Thaysen , CEO of Illumina. "As we prepare to lead the next era of genomics innovation, we believe GRAIL will play an important role in advancing the industry and improving human health. We will maintain a minority share of 14.5% in GRAIL and remain excited about GRAIL's breakthroughs in the fight against cancer. We also look forward to exploring opportunities where we can support GRAIL's work with industry-leading technologies and solutions."

Cunningham previously served as CCO for Exact Sciences and brings more than   20 years of commercial leadership across healthcare tech, life sciences, and pharma

- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago . Highlights include data from several studies in partnership with Labcorp, a global leader of innovative and comprehensive laboratory services; research with Sarah Cannon Research Institute (SCRI) demonstrating further evidence to support the use of comprehensive genomic profiling (CGP) over single-gene testing (SGT); and the latest data supporting the development of Illumina's molecular residual disease (MRD) assay, which is currently underway in collaboration with major pharma companies. In total, Illumina had 14 abstracts accepted to the meeting.

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving as a champion for patients, communities, employees, and the planet.

"At Illumina, we are guided by our mission to improve human health by unlocking the power of the genome," said Jacob Thaysen , CEO of Illumina. "Our customers, partners, and employees continue taking bold, meaningful steps to accelerate access to genomics, empower our communities, integrate environmental sustainability into our business strategy, nurture our people, and operate responsibly."

Illumina's CSR program is rooted in four key focus areas, and the company's 2023 CSR Report demonstrates progress in each:

• Accelerating access to genomics : Illumina continues to bring the benefits of genomics to more people by driving down the cost of sequencing, expanding into new markets, and increasing the diversity of genomic data. In 2023, Illumina trained more than 27,000 health care professionals and continued its advocacy for health care coverage for genomic testing, which increased from 1.2 billion to 1.3 billion. The company also launched several new products, including the NovaSeq™ X Series, powered by XLEAP-SBS™ chemistry; the TruSight™ Oncology 500 ctDNA v2 research assay, enabling comprehensive genomic profiling from liquid biopsy samples; and the 25B flow cell, which can generate tens of thousands of whole genomes per year at the lowest cost per sample of any Illumina platform.
  
  
• Nurturing our people and communities : In 2023, Illumina maintained a zero net pay gap for the fifth consecutive year and reached 45% female representation in the workforce, with a 5% increase in female leadership roles over the last three years. Illumina also strives to create a purpose-driven culture, and in 2023, nearly 60% of employees worldwide participated in charitable giving and volunteering.
  
• Integrating environmental stewardship : As the genomics industry leader, Illumina plays a crucial role in contributing to a healthier planet. The Illumina NovaSeq X Series, which debuted in 2023, uses significantly more sustainable reagents, resulting in 90% less packaging weight and waste, 50% less plastic, and a 61% reduction in climate change impact. Additionally, 100% of Illumina's global electricity consumption came from renewable sources for the second consecutive year.
  
• Operating responsibly : In 2023, Illumina strengthened its dedication to ethical business practices and operational integrity by ensuring that 100% of its core facilities participated in third-party audit programs. Illumina also expanded its ISO data privacy certification to include additional products and completed the EU-US and Swiss-US Data Privacy Framework (DPF) Self-Certification and ISO 27701 certification. Additionally, Illumina continues to exercise strong corporate governance with an independent Board of Directors (all independent with the exception of the CEO), an independent Board Chair, and 75% of standing committees chaired by women.

The full report is available on Illumina's CSR website .

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the future, business plans and other statements that are not historical in nature. These statements are made on the basis of Illumina's views and assumptions regarding future events and business performance and plans as of the time the statements are made. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. Illumina does not undertake any obligation to update these statements unless required by applicable laws or regulations, and you should not place undue reliance on forward-looking statements. Specific factors are set forth in Illumina's Annual Report on Form 10-K for the year ended January 1, 2023 under the caption "Risk Factors", in information disclosed in public conference calls, the date and time of which are released beforehand, and in filings with the Securities and Exchange Commission including, among others, quarterly reports on Form 10-Q.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X , Facebook , LinkedIn , Instagram , TikTok , and YouTube .

Contacts

Investors:  
Salli Schwartz
858-291-6421
IR@illumina.com

Media:  
Samantha Beal
PR@illumina.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/illumina-releases-2023-corporate-social-responsibility-report-302157056.html

SOURCE Illumina, Inc.

Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience   to Illumina's Board

Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024 annual meeting. Ms. Richo currently serves as Corporate Senior Vice President, Strategic Advisor to the General Counsel and CEO at Cargill, Inc. a global food production and agricultural company.